

Supply Chain Coordination During COVID-19

During the first 90 days, the American pharmaceutical supply chain was resilient and effective in responding to the global pandemic.



MANUFACTURER

- Identified in-demand medicines and scaled capacity
- Minimized material disruptions by working with suppliers
- Supported clinical trials for existing medicines used in exploratory COVID-19 treatments

DISTRIBUTOR

- Leveraged strong relationships, logistics expertise and prior emergency response experience
- Established “fair share” allocation programs
- Identified alternative manufacturing sources and sourced back-up products, where possible
- Moved products to COVID-19 “hot spots” while meeting the daily healthcare needs of all Americans
- Coordinated with partners to anticipate changes in demand and mitigate disruptions

HEALTHCARE PROVIDER/FACILITY

- Shared regular updates of number of COVID-19 admissions and ICU capacity
- Reported which COVID-19 therapies were being used to better inform demand forecasting
- Used alternative therapy regimes



Medicine and product flows



Demand data flow



Healthcare Distribution Alliance

PATIENTS MOVE US.

For additional resources, visit [HDA.org](https://www.hda.org) | Follow us on Twitter: [@HDAconnect](https://twitter.com/HDAconnect)

Source: Healthcare Distribution Alliance Research Foundation. *The First 90 Days: US Biopharmaceutical Finished Goods Supply Chain Response to COVID-19 (2020)*